Clinical Trial Update: Pyridoxal Kinase Activity in Tardive Dyskinesia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating pyridoxal kinase activity in tardive dyskinesia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Snippet

Sponsor: Beersheva Mental Health Center | Conditions: Tardive Dyskinesia | Phase 3 | Status: WITHDRAWN